176 related articles for article (PubMed ID: 25878009)
21. MxA mRNA decrease preceding NAb detection in IFNβ-treated MS patients.
Libertinova J; Meluzinova E; Matoska V; Zajac M; Kovarova I; Havrdova E; Horakova D; Tomek A; Marusic P; Bojar M
Brain Behav; 2017 Mar; 7(3):e00644. PubMed ID: 28293479
[TBL] [Abstract][Full Text] [Related]
22. BAb and MxA as functional biomarkers in routine clinical laboratories for the determination of anti-IFN-beta antibodies and their bioactivity levels in multiple sclerosis patients.
Cakal B; Uygunoglu U; Saip S; Altintas A; Siva A; Badur S
J Immunoassay Immunochem; 2014; 35(4):398-411. PubMed ID: 24547871
[TBL] [Abstract][Full Text] [Related]
23. In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent.
Sominanda A; Hillert J; Fogdell-Hahn A
J Neurol Neurosurg Psychiatry; 2008 Jan; 79(1):57-62. PubMed ID: 17911184
[TBL] [Abstract][Full Text] [Related]
24. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
25. IFNbeta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays.
Capra R; Sottini A; Cordioli C; Serana F; Chiarini M; Caimi L; Padovani A; Bergamaschi R; Imberti L
J Neuroimmunol; 2007 Sep; 189(1-2):102-10. PubMed ID: 17619058
[TBL] [Abstract][Full Text] [Related]
26. Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis.
van der Voort LF; Visser A; Knol DL; Oudejans CB; Polman CH; Killestein J
Eur J Neurol; 2009 Sep; 16(9):1049-52. PubMed ID: 19486142
[TBL] [Abstract][Full Text] [Related]
27. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
van der Voort LF; Kok A; Visser A; Oudejans CB; Caldano M; Gilli F; Bertolotto A; Polman CH; Killestein J
Mult Scler; 2009 Feb; 15(2):212-8. PubMed ID: 18805837
[TBL] [Abstract][Full Text] [Related]
28. Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis.
Link J; Lundkvist Ryner M; Fink K; Hermanrud C; Lima I; Brynedal B; Kockum I; Hillert J; Fogdell-Hahn A
PLoS One; 2014; 9(3):e90479. PubMed ID: 24608124
[TBL] [Abstract][Full Text] [Related]
29. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.
Farrell RA; Espasandin M; Lakdawala N; Creeke PI; Worthington V; Giovannoni G
Mult Scler; 2011 Nov; 17(11):1333-40. PubMed ID: 21685230
[TBL] [Abstract][Full Text] [Related]
30. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.
Deisenhammer F; Schellekens H; Bertolotto A
J Neurol; 2004 Jun; 251 Suppl 2():II31-9. PubMed ID: 15264110
[TBL] [Abstract][Full Text] [Related]
31. A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta.
Kob M; Harvey J; Schautzer F; Kascha S; Bibl D; Egg R; Reindl M; Berger T; Deisenhammer F
Mult Scler; 2003 Feb; 9(1):32-5. PubMed ID: 12617265
[TBL] [Abstract][Full Text] [Related]
32. Are corticosteroids efficacious for preventing or treating neutralizing antibodies in multiple sclerosis patients treated with beta-interferons? A critically appraised topic.
Zarkou S; Carter JL; Wellik KE; Demaerschalk BM; Wingerchuk DM
Neurologist; 2010 May; 16(3):212-4. PubMed ID: 20445436
[TBL] [Abstract][Full Text] [Related]
33. Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow-up study.
Garcia-Montojo M; Dominguez-Mozo MI; de las Heras V; Bartolome M; Garcia-Martinez A; Arroyo R; Alvarez-Lafuente R
Eur J Neurol; 2010 Mar; 17(3):470-8. PubMed ID: 20050906
[TBL] [Abstract][Full Text] [Related]
34. Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ.
Libertinova J; Meluzinova E; Tomek A; Horakova D; Kovarova I; Matoska V; Kumstyrova S; Zajac M; Hyncicova E; Liskova P; Houzvickova E; Martinkovic L; Bojar M; Havrdova E; Marusic P
PLoS One; 2017; 12(1):e0169957. PubMed ID: 28081207
[TBL] [Abstract][Full Text] [Related]
35. MxA protein induction in MS patients treated with intramuscular IFNbeta-1a.
Vallittu AM; Salmi AA; Erälinna JP;
Neurol Sci; 2006 Feb; 26(6):438-43. PubMed ID: 16601938
[TBL] [Abstract][Full Text] [Related]
36. A comparative study of the relative bioavailability of different interferon beta preparations.
Deisenhammer F; Mayringer I; Harvey J; Dilitz E; Gasse T; Stadlbauer D; Reindl M; Berger T
Neurology; 2000 Jun; 54(11):2055-60. PubMed ID: 10851362
[TBL] [Abstract][Full Text] [Related]
37. Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-β.
Hesse D; Frederiksen JL; Koch-Henriksen N; Schreiber K; Stenager E; Heltberg A; Ravnborg M; Bendtzen K; Sellebjerg F; Sorensen PS
Eur J Neurol; 2009 Jan; 16(1):43-7. PubMed ID: 19087149
[TBL] [Abstract][Full Text] [Related]
38. Antibody dissociation rates are predictive of neutralizing antibody (NAb) course: a comparison of interferon beta-1b-treated Multiple Sclerosis (MS) patients with transient versus sustained NAbs.
Gibbs E; Karim ME; Oger J;
Clin Immunol; 2015 Mar; 157(1):91-101. PubMed ID: 25543089
[TBL] [Abstract][Full Text] [Related]
39. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.
Gilli F; Bertolotto A; Sala A; Hoffmann F; Capobianco M; Malucchi S; Glass T; Kappos L; Lindberg RL; Leppert D
Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790
[TBL] [Abstract][Full Text] [Related]
40. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
Bertolotto A; Sala A; Caldano M; Capobianco M; Malucchi S; Marnetto F; Gilli F
J Immunol Methods; 2007 Apr; 321(1-2):19-31. PubMed ID: 17335844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
